Gilead Sciences, Inc. vs Williams Companies Inc — how do they compare? Gilead Sciences, Inc. trades at $135.19 (market cap $168.35B), while Williams Companies Inc trades at $71.97 (market cap $88.45B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Williams Companies Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals.
| GILD | WMB | |
|---|---|---|
Market Cap | $168.35B | $88.45B |
Sector | Health | Energy |
52-Week High | $155.80 | $79.40 |
52-Week Low | $110.56 | $56.51 |
Enterprise Value | $191.42B | $119.07B |
Dividend Yield | 2.42% | 2.9% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →